Literature DB >> 9215275

Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in prepubertal children with exogenous obesity: effect of short- and long-term weight reduction.

J Argente1, N Caballo, V Barrios, J Pozo, M T Muñoz, J A Chowen, M Hernández.   

Abstract

We have studied the GH-insulin-like growth factor (IGF) axis in prepubertal children with exogenous obesity at the time of clinical diagnosis and at two time points during weight reduction on a calorie-restricted diet. Spontaneous GH secretion, IGF-I, free IGF-I (fIGF-I), IGF-II, their binding proteins (IGFBP-1, IGFBP-2, and IGFBP-3), and GH-binding protein (GHBP) values at the time of clinical diagnosis (n = 65), after a 25% decrease in the body mass index (BMI) expressed as the SD score (BMI SD score; n = 29), and after a diminution of at least 50% of the initial BMI SD score (n = 9) are reported. GH secretion was significantly reduced at diagnosis, and after a decrease of at least 25% in the initial BMI SD score, it returned to normal in all patients. Total IGF-I levels were not significantly different from those in controls at any point. In contrast, fIGF-1 and IGF-II levels were significantly increased, both at diagnosis and after BMI SD score reduction. Obese patients were hyperinsulinemic at diagnosis and remained so even after a 50% reduction of their BMI SD score. Serum IGFBP-1 and IGFBP-2 levels were significantly decreased at diagnosis and at the two points studied during weight reduction. Serum IGFBP-3 and GHBP levels were increased significantly at diagnosis and returned to normal levels after a reduction in the BMI SD score. A positive correlation between serum GHBP levels and BMI was found in both controls and obese patients. Serum IGFBP-3 levels correlated positively with IGF-I, fIGF-I, and IGF-II in all groups, but these correlations were weaker in the obese patients at diagnosis. IGFBP-2 correlated significantly with IGF-II only in the obese group at diagnosis (r = -0.760; P < 0.0001), but with fIGF-I in all groups. IGFBP-1 was negatively correlated with IGF-I and fIGF-I in all groups. In conclusion, the GH-IGF axis is dramatically altered in patients with exogenous obesity. However, most changes in the peripheral IGF system appear to be independent of the modifications in GH secretion. In addition, in contrast to current thought, not all of the observed abnormalities are reversed with a significant reduction in the BMI SD score.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9215275     DOI: 10.1210/jcem.82.7.4089

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  29 in total

Review 1.  Growth hormone therapy in the Prader-Willi syndrome.

Authors:  W F Paterson; M D C Donaldson
Journal:  Arch Dis Child       Date:  2003-04       Impact factor: 3.791

2.  The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: effects of long-term interdisciplinary therapy.

Authors:  Raquel M S Campos; Aline de Piano; Patrícia L da Silva; June Carnier; Priscila L Sanches; Flávia C Corgosinho; Deborah C L Masquio; Marise Lazaretti-Castro; Lila M Oyama; Cláudia M O Nascimento; Lian Tock; Marco Túlio de Mello; Sergio Tufik; Ana R Dâmaso
Journal:  Endocrine       Date:  2012-08       Impact factor: 3.633

Review 3.  The metabolic effects of growth hormone in adipose tissue.

Authors:  Valéria Ernestânia Chaves; Fernando Mesquita Júnior; Gisele Lopes Bertolini
Journal:  Endocrine       Date:  2013-02-21       Impact factor: 3.633

4.  Improvement in growth after 1 year of growth hormone therapy in well-nourished infants with growth retardation secondary to chronic renal failure: results of a multicenter, controlled, randomized, open clinical trial.

Authors:  Fernando Santos; M Llanos Moreno; Arlete Neto; Gema Ariceta; Julia Vara; Angel Alonso; Alberto Bueno; Alberto Caldas Afonso; António Jorge Correia; Rafael Muley; Vicente Barrios; Carlos Gómez; Jesús Argente
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-03       Impact factor: 8.237

5.  Adolescent obesity, bone mass, and cardiometabolic risk factors.

Authors:  Norman K Pollock; Paul J Bernard; Bernard Gutin; Catherine L Davis; Haidong Zhu; Yanbin Dong
Journal:  J Pediatr       Date:  2011-01-13       Impact factor: 4.406

6.  Dwarfism and increased adiposity in the gh1 mutant zebrafish vizzini.

Authors:  Sarah K McMenamin; James E N Minchin; Tiffany N Gordon; John F Rawls; David M Parichy
Journal:  Endocrinology       Date:  2013-03-01       Impact factor: 4.736

7.  Adiposity and TV viewing are related to less bone accrual in young children.

Authors:  Karen S Wosje; Philip R Khoury; Randal P Claytor; Kristen A Copeland; Heidi J Kalkwarf; Stephen R Daniels
Journal:  J Pediatr       Date:  2008-08-09       Impact factor: 4.406

8.  A pilot study of the effects of niacin administration on free fatty acid and growth hormone concentrations in children with obesity.

Authors:  O A Galescu; M K Crocker; A M Altschul; S E Marwitz; S M Brady; J A Yanovski
Journal:  Pediatr Obes       Date:  2016-09-21       Impact factor: 4.000

9.  Prevalence and phenotypic characterization of MC4R variants in a large pediatric cohort.

Authors:  H Vollbach; S Brandt; G Lahr; C Denzer; J von Schnurbein; K-M Debatin; M Wabitsch
Journal:  Int J Obes (Lond)       Date:  2016-09-22       Impact factor: 5.095

10.  Effect of body mass index on peak growth hormone response to provocative testing in children with short stature.

Authors:  Takara L Stanley; Lynne L Levitsky; Steven K Grinspoon; Madhusmita Misra
Journal:  J Clin Endocrinol Metab       Date:  2009-11-04       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.